<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Between 1989 and 1998 93 patients with malignant <z:hpo ids='HP_0002665'>lymphoma</z:hpo> were treated, in our centre, with high-dose chemotherapy and autologous stem cell transplantation </plain></SENT>
<SENT sid="1" pm="."><plain>Diagnosis according to the REAL-classification were: 38 patients with high-grade <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (DLCL) (n = 26), anaplastic T-cell (n = 5), lymfoblastic (n = 3) and others (n = 4)), 31 patients with low-grade <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (follicular (n = 18), mantle cell (n = 4), B-CLL (n = 3) and others (n = 6)) and, finally, 24 patients with <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>The source of stem cells was bone marrow (14 patients), peripheral blood stem cells (64 patients) or a combination of both sources (15 patients) </plain></SENT>
<SENT sid="3" pm="."><plain>There was no early ( &lt; 100 days) transplant-related mortality </plain></SENT>
<SENT sid="4" pm="."><plain>One patient died 11 months post-transplant in unexplained <z:hpo ids='HP_0001399'>liver failure</z:hpo> and <z:hpo ids='HP_0000001'>all</z:hpo> other causes of <z:hpo ids='HP_0011420'>death</z:hpo> were related to relapse of <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>So far, no case of <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> or secondary <z:hpo ids='HP_0011009'>acute</z:hpo> leukacmia's has occurred </plain></SENT>
<SENT sid="6" pm="."><plain>Overall survival (OS) and progression-free survival (PFS) are: (a) DLCL (26 patients, 4-year probability) OS 40% </plain></SENT>
<SENT sid="7" pm="."><plain>PFS 33%; (b) follicular (18 patients, 3-year probability) OS 79%, PFS 52%; (c) Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (24 patients, 5-year probability) OS 65%, PFS 55% </plain></SENT>
<SENT sid="8" pm="."><plain>Out of 52 evaluable patients, 34 (65%) have reached remission inversion </plain></SENT>
<SENT sid="9" pm="."><plain>The most important findings are no early transplantation-related mortality, remission inversion in a majority of patients, and so far no cases of secondary <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) <z:hpo ids='HP_0011009'>acute</z:hpo> myelogenous <z:mpath ids='MPATH_336'>leukaemias</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="10" pm="."><plain>Concerning OS and PFS, our results seem to be in accordance with other centres </plain></SENT>
</text></document>